[EN] 7-PHENYL-ISOQUINOLINE-5-SULFONYLAMINO DERIVATIVES AS INHIBITORS OF AKT (PROTEINKINASE B)<br/>[FR] DERIVES DE 7-PHENYL-ISOQUINOLINE-5-SULFONYLAMINO EN TANT QU'INHIBITEURS DE AKT (PROTEINE KINASE B)
申请人:LILLY CO ELI
公开号:WO2005054202A1
公开(公告)日:2005-06-16
The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
本发明涉及化合物式(I)作为AKT活性抑制剂,用于治疗易感的肿瘤和病毒感染。
Features of Auxiliaries That Enable Native Chemical Ligation beyond Glycine and Cleavage via Radical Fragmentation
作者:Simon F. Loibl、Andre Dallmann、Kathleen Hennig、Carmen Juds、Oliver Seitz
DOI:10.1002/chem.201705927
日期:2018.3.7
Nativechemicalligation (NCL) is an invaluable tool in the total chemical synthesis of proteins. Ligationauxiliaries overcome the requirement for cysteine. However, the reported auxiliaries remained limited to glycine‐containing ligation sites and the acidic conditions applied for cleavage of the typically applied N‐benzyl‐type linkages promote side reactions. With the aim to improve upon both ligation
Photodegradable antimicrobial agents − synthesis, photodegradation, and biological evaluation
作者:Vebjørn Eikemo、Leiv K. Sydnes、Magne O. Sydnes
DOI:10.1039/d1ra06324c
日期:——
(MDR) bacteria are already a significant health-care problem and are making the combat of infections quite challenging. Here we report the synthesis of several new compounds containing an ethanolamine moiety, of which two exhibit promising antimicrobial activity (at the 6 μM level). All the compounds are degraded when exposed to light and form inactive products.
7-Phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
申请人:Barda Anthony David
公开号:US20070037796A1
公开(公告)日:2007-02-15
The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
本发明涉及化合物式(I)作为AKT活性抑制剂,其对易感肿瘤和病毒感染的治疗有用。
7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
申请人:Eli Lilly and Company
公开号:US07449477B2
公开(公告)日:2008-11-11
The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.